Joan Pitkin, Margaret C P Rees, Sarah Gray, Mary Ann Lumsden, Jo Marsden, John Stevenson, Jennifer Williamson
{"title":"Managing the menopause: British Menopause Society Council consensus statement on hormone replacement therapy.","authors":"Joan Pitkin, Margaret C P Rees, Sarah Gray, Mary Ann Lumsden, Jo Marsden, John Stevenson, Jennifer Williamson","doi":"10.1258/136218005775544354","DOIUrl":null,"url":null,"abstract":"<p><p>The British Menopause Society Council aims to help health professionals inform and advise women about the menopause. This guidance regarding estrogen-based hormone replacement therapy (HRT), including tibolone, which is classified in the British National Formulary as HRT, responds to the results and analysis of the randomized Women's Health Initiative studies and the observational Million Women Study. Treatment choice should be based on up-to-date information and targeted to individual women's needs. HRT still offers the potential for benefit to outweigh harm, providing the appropriate regimen has been instigated in terms of dose, route and combination.</p>","PeriodicalId":85745,"journal":{"name":"The journal of the British Menopause Society","volume":"11 4","pages":"152-6"},"PeriodicalIF":0.0000,"publicationDate":"2005-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1258/136218005775544354","citationCount":"31","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of the British Menopause Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1258/136218005775544354","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 31
Abstract
The British Menopause Society Council aims to help health professionals inform and advise women about the menopause. This guidance regarding estrogen-based hormone replacement therapy (HRT), including tibolone, which is classified in the British National Formulary as HRT, responds to the results and analysis of the randomized Women's Health Initiative studies and the observational Million Women Study. Treatment choice should be based on up-to-date information and targeted to individual women's needs. HRT still offers the potential for benefit to outweigh harm, providing the appropriate regimen has been instigated in terms of dose, route and combination.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
